Release Date: December 2025
Number of Pages: 273
Tables and Figures: 89
Pipeline Candidates: 216
The “Dermatological Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.
The report covers market sizing & forecasts from 2025 – 2035 period which are segmented across seven therapeutic categories, three routes of administration, two drug types (OTC vs. Prescription), four distribution channels, three major drug classes (biologics, small molecules, gene & emerging therapies), and 26 leading countries across five regions.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset.

For Enquiries, Press, Sample Pages and Table of Contents Please Contact: [email protected]

The Dermatological Drugs Market: 2025 – 2035 - Opportunities, Challenges, Strategies & Forecasts​

Synopsis: The global dermatological drugs market is experiencing robust growth, driven by rising prevalence of skin disorders, persistent unmet medical needs, and increased demand for innovative therapies. Companies are strategically targeting diverse and previously underserved conditions, with breakthroughs across biologics, biosimilars, and novel therapeutic classes reshaping the competitive landscape. These innovations are delivering highly targeted, high-efficacy treatments across major therapeutic areas, including psoriasis, atopic dermatitis, alopecia areata, and skin cancer, and redefining standards of care.

Dermatological drugs remain the largest segment of spending within the broader dermatology market, projected to reach $52.8 billion globally by 2025. They continue to serve as the primary treatment option for both common conditions, such as acne, and complex diseases, including psoriasis. While patent expirations have introduced generic competition, the market outlook remains robust, supported by several late-stage and near-market drug candidates.

Biologics have emerged as a key growth driver, offering targeted treatment options for chronic conditions and providing targeted options for patients unresponsive to traditional therapies. Complementing this, innovations in drug delivery systems, particularly advanced topical platforms and microneedle technologies, are improving penetration, tolerability, and patient adherence, further supporting market expansion.

The “Dermatological Drugs Market: 2025 – 2035 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.
The report covers market sizing & forecasts from 2025 – 2035 period which are segmented across seven therapeutic categories, three routes of administration, two drug types (OTC vs. Prescription), four distribution channels, three major drug classes (biologics, small molecules, gene & emerging therapies), and 26 leading countries across five regions.
Pricing: Single User to Global Access

​Single User License: USD 3,000
Company Wide License (Single Site): USD 4,500
Company Wide License (Global Site): USD 7,500

For a Sample and Table of Contents please contact: [email protected]
Topics Covered:
The report covers the following topics:
  • Dermatological drugs ecosystem
  • Market drivers and barriers
  • Dermatological disorders, application areas and key trends
  • Analysis of key drug classes and leading dermatological drugs
  • Future drug development pipeline
  • Dermatological drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of 83 leading ecosystem players, including dermatological drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2025 till 2035
Sample Figure:
Sample Figure: Distribution of Dermatological Pipeline Candidates by Developmental Phase (%)
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset, profiling 216 drug candidates.
For a Sample and Table of Contents please contact: [email protected]​
Key Findings: The report has the following key findings
  • Global dermatological drug spending is projected to reach approximately $52.8 billion in 2025, driven by sustained demand across inflammatory and chronic skin diseases.
 
  • Advanced biologics remain the primary growth engine, supported by high-impact approvals and label expansions across atopic dermatitis, urticaria, prurigo nodularis, and psoriasis.
 
  • IL-23 inhibitors (risankizumab, guselkumab) and dual-pathway IL-17 agents (bimekizumab) are setting the new standard for long-term, durable control of moderate-to-severe disease, reflecting the market’s move toward deep, cytokine-specific immunology.
 
  • TYK2 inhibitors, led by deucravacitinib, are reshaping competitive dynamics by offering targeted efficacy with the convenience of oral dosing, positioning them as credible alternatives to injectables.
 
  • Innovation in topical agents such as JAK-based creams and PDE4 inhibitors continues to strengthen, improving localized therapeutic control and expanding treatment options for chronic inflammatory conditions.
 
  • The 2025 commercial entry of multiple ustekinumab biosimilars marks a structural shift in pricing and access, prompting originators to deploy aggressive lifecycle and payer-defense strategies.
​
  • Strategic acquisitions and alliances remain central to growth. Notable examples include J&J’s acquisition of Proteologix, adding two bispecific antibodies for atopic dermatitis and reinforcing the industry-wide pivot toward precision immunology.
Key Questions Answered:
The report provides answers to the following key questions
  • How big is the dermatological drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2025 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in dermatology?
  • What are the key drug delivery technologies being used in dermatological treatments?
  • How big is the market for psoriasis drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should dermatological drug manufacturers adopt to remain competitive?​
Sample Figure:
Sample Figure: Global Dermatology Product Spending by Submarket (%)
Forecast Segmentation:
The report provides detailed forecasts across multiple dimensions of the dermatological drugs market, including:
  • Therapeutic Category
    • Acne & Rosacea
    • Alopecia & Hair Disorders
    • Dermatitis
    • Psoriasis
    • Skin Infections
    • Skin Cancer
    • Other Conditions
  • Drug Delivery Route
    • Topical
    • Oral
    • Parenteral Formulations
  • Drug Type
    • Over-the-Counter (OTC)
    • Prescription​​​​
  • Distribution Channel
    • Point-of-Care/Clinic
    • Retail Pharmacies
    • Digital Pharmacies
    • Direct-to-Consumer (D2C)
  • Drug Class
    • Biologics
      • IL-23
      • IL-17
      • IL-4/13
      • TNF inhibitors
      • IL-12/23 & Others
    • Small Molecules
      • Corticosteroids
      • Retinoids
      • Calcineurin inhibitors
      • PDE4 inhibitors
      • JAK inhibitors
      • Anti-infectives
      • Vitamin D analogues
      • Others
    • Gene & Emerging Therapies 
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America​​
  • ​Country Markets
    • Australia
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA​​
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report
3M
Abbott Laboratories
AbbVie
Abeona Therapeutics
AbGenomics Holding
AboundBio
Absci Corporation
Aclaris Therapeutics
Actelion Pharmaceuticals
Adaptimmune
AiCuris
Akouos
Akros Pharma
Alfasigma
Allergan
Almirall
AltruBio
Amgen
Amplyx Pharmaceuticals
Amryt Pharma
Anacor Pharmaceuticals
AnaptysBio
AndroScience Corporation
AnnJi Pharmaceutical
AOBiome
ApoPharma
Apotex
Arcutis Biotherapeutics
Arena Pharmaceuticals
Array BioPharma
Asana BioSciences
Astellas Pharma
AstraZeneca
Astria Therapeutics
Autotelic
Bausch Health Companies
Bayer Pharmaceuticals
Bill and Melinda Gates Foundation
Biocon Biologics
Biocon Generics
Biofrontera
BioGen
Biomedical Advanced Research and Development Authority (BARDA) 
BioMimetix
BioOne Capital
BioRay Pharmaceutical
Biosintez
Bio-Thera Solutions
Boehringer Ingelheim
Botanix Pharmaceuticals
BPGbio
Bristol-Myers Squibb
Cadila Pharmaceuticals
Can-Fite BioPharma
Cantharidin Pharmaceuticals
Capella BioScience
Care Capital
Castle Creek Biosciences
Celgene
CellPoint
Celltrion
Cerbios-Pharma
Checkmate Pharmaceuticals
Chiesi Farmaceutici
Chugai Pharmaceutical
Cipher Pharmaceuticals
CKD Pharmaceuticals
Clarion Medical Technologies
Clinuvel Pharmaceuticals
Coherus BioSciences
Concert Pharmaceuticals
CorMedix
Cosette Pharmaceuticals
Cosmo Pharmaceuticals
CSL Behring
Cumberland Pharmaceuticals
Cutanea Life Sciences
Daewoong Pharmaceutical
Debiopharm
Dermata Therapeutics
Dermavant Sciences
DermBiont
Dermira
DFB Soria
DICE Therapeutics
Dow Pharmaceutical
Dr. Reddy’s Laboratories
Durata Therapeutics
Dusa Pharmaceuticals
Eirion Therapeutics
Eli Lilly and Company
Elorac
Elsie Biotechnologies
EMD Serono
Encore Dermatology
Escalier Biosciences
Escient Pharmaceuticals
European Medicines Agency (EMA)
Evolus
Ewopharma
Exelixis
Eywa Pharma
F. Hoffmann-La Roche
FAES Farma
FDA
Fibrocell Science
G&E Herbal Biotechnology
Galapagos
Galderma
Galectin Therapeutics
Genentech
Gilead Sciences
Glenmark Pharmaceuticals
GSK (GlaxoSmithKline)
Gurnet Point
Gurnet Point Capital
Hallux
Hapten Sciences
Horizon Therapeutics
Hospira
Hoth Therapeutics
Huya Bioscience
Ichnos Glenmark Innovation
Ichnos Sciences
Immunocore
Immutep
Incyte Corporation
Innovation Pharmaceuticals
InSite Vision
Iovance Biotherapeutics
Ipsen
Janssen Pharmaceutical
Janssen Research & Development
Japan Tobacco
Jiangsu Hengrui Medicine
Johnson & Johnson
Journey Medical Corporation
Kiniksa Pharmaceuticals
Kintara Therapeutics
Krystal Biotech
Kyowa Kirin
Ladrôme
LEO Pharma
Libertas Bio
Ligand Pharmaceuticals
Lipidor
Maruho
Mayne Pharma
MB Venture Partners
Meda Pharma
Melinta Therapeutics
Merck & Co
Merck KGaA
Merz Pharma
Microsoft
Moderna
MorphoSys
Mycovia Pharmaceuticals
Mylan
Nanology
Nestlé Skin Health
Neumedicines
Nielsen BioSciences
Novartis
Novo Holdings
Oncolys Biopharma
Oncotelic
Ono Pharmaceutical
Optinose
OriCiro Genomics
Ortho Dermatologics
Paratek Pharmaceuticals
Pelthos Therapeutics
Pfizer
Philogen
Phio Pharmaceuticals
Photogen Technologies
Pierre Fabre
Pierre Fabre Laboratories
Poli Group
Polpharma Biologics
PolyMedix
Precigen
Prevail Therapeutics
Principia Biopharma
Priovant Therapeutics
Promius Pharma
ProQR Therapeutics
Proteologix
Protomer Technologies
Provectus Biopharmaceuticals
Pyxis Oncology
Qurient
Ralexar Therapeutics
Ranbaxy Laboratories
Rani Therapeutics
Regeneron Pharmaceuticals
Roche
Roivant Sciences
Samsung
Samsung Bioepis
Sandoz AG
Sanofi
SBI Biotech
Searchlight Pharma
Seattle Genetics
Sierra Oncology
Sinclair Pharma
Sol-Gel Technologies
Soligenix
Stiefel Laboratories
Sun Pharmaceutical Industries
Takeda
Takeda Oncology
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The Proactiv Company
Timber Pharmaceuticals
Tioga Pharmaceuticals
Torii Pharmaceutical
Trillium Therapeutics
UCB Biopharma
UNION Therapeutics
University of Pennsylvania 
Upjohn
URL Pharma
US WorldMeds
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Vectans Pharma
Verrica Pharmaceuticals
VidacPharma
Villaris Therapeutics
Vyne Therapeutics
Zydus Group